MedTrace Logo

Pro-active Genetic Testing in Kidney Transplant Patients

NCT05298904 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 177

Last updated 2026-01-27

No results posted yet for this study

Summary

The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.

Conditions

  • Kidney Transplant

Interventions

DIAGNOSTIC_TEST

Genetic Health Screen Panel

This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).

Sponsors & Collaborators

Principal Investigators

  • Girish Mour, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2037-03-01
Completion
2038-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05298904 on ClinicalTrials.gov